CEL-SCI secures $7.2M from a 6M share offering to fund drug development and corporate needs.
CEL-SCI priced a public offering of 6M shares at $1.20 each, raising approximately $7.2M in gross proceeds. The funds will support Multikine development, general corporate purposes, and working capital.
The offering is set to close on May 13, 2026. Prior to the announcement, the company’s stock fell about 10% in pre-market trading on Tuesday.
Proceeds exclude placement agent fees and other expenses, with no immediate market reaction details provided beyond the pre-market decline.